“The Year of Ozempic” proclaimed the December 2023 edition of The New Yorker.

That same month, the journal Science declared glucagon-like peptide-1 (GLP-1) weight loss drugs its “Breakthrough of the Year,” beating out commendable contenders such as new malaria and Alzheimer’s treatments, innovative climate change research on natural carbon pumps and artificial intelligence (AI) in improving weather forecasting. Apparently, Science viewed treating obesity as a bigger story than dementia and global warming.

With all the success of human obesity medications, could pet weight loss drugs be far behind?

Veterinary and human healthcare professionals often use the term “obese” to describe a patient with excess body fat. Calling a patient “obese” has significant negative connotations and can be stigmatizing and emotionally triggering.

In veterinary medicine, labeling a pet as “obese” can imply that the owner has failed to provide proper care and nutrition, potentially causing feelings of unease and criticism. It shifts the focus from underlying physiological causes such as genetics, microbiome, hormonal imbalances, and other biological factors to lifestyle choices like exercise and diet.

On the other hand, the proposed terminology, such as “the dog has obesity, ” “a cat having obesity,” or “a pet with obesity,” focuses on the disease state rather than the physical appearance, thereby avoiding blame on the pet owner's actions or an animal’s behavior or inherent characteristic.